Revenue Performance - Total consolidated reported revenues for Q4 2024 were $2.56 billion, a 6% increase from $2.41 billion in Q4 2023, with organic revenue growth of 9%[4] - Full-year 2024 consolidated revenues reached $9.63 billion, up 10% from $8.76 billion in 2023, with organic revenue growth of 8%[4] - Product sales for Q4 2024 reached $2,528 million, a 6.1% increase from $2,382 million in Q4 2023[51] - Total revenues for the twelve months ended December 31, 2024, were $9,625 million, up 9.9% from $8,757 million in 2023[51] - Total revenues for Bausch Health Companies Inc. for the three months ended December 31, 2024, were $2.582 billion, an increase of 6% from $2.408 billion in 2023[64] - Bausch + Lomb's total revenue was $4,791 million, a 16% increase from $4,146 million in 2023[66] Segment Performance - The Salix segment reported Q4 revenues of $634 million, a 9% increase year-over-year, with organic growth of 12% after excluding divestitures[6] - The Solta Medical segment saw Q4 revenues of $138 million, a 34% increase, with organic growth of 35%[8] - The Bausch + Lomb segment reported Q4 revenues of $1.28 billion, a 9% increase, with organic growth of 10%[10] - Salix segment revenue reached $2,333 million, up 4% from $2,250 million in the previous year[66] - Solta Medical segment showed significant growth with revenue of $440 million, a 27% increase from $347 million in 2023[66] - Bausch Health's Pharmaceuticals segment revenue was $1,209 million, reflecting a 45% increase from $836 million in 2023[66] Profitability Metrics - Adjusted EBITDA for Q4 2024 was $935 million, an 8% increase from $869 million in Q4 2023, while full-year adjusted EBITDA was $3.31 billion, up 10% from $3.01 billion[16] - Consolidated net income for Q4 2024 was $93 million, compared to a net loss of $39 million in Q4 2023, marking a favorable change of $132 million[13] - Operating income for Q4 2024 was $558 million, compared to $362 million in Q4 2023, reflecting a 54.1% increase[51] - Adjusted net income for the twelve months ended December 31, 2024, was $1.394 billion, an increase from $1.274 billion in 2023, reflecting a growth of 9.4%[52] - Adjusted EBITDA for the twelve months ended December 31, 2024, was $3.425 billion, an increase from $3.110 billion in 2023, reflecting a growth of 10.1%[62] Cash Flow and Debt Management - Cash provided by operating activities was $601 million for Q4 2024, compared to $390 million in Q4 2023, reflecting improved business performance[16] - Cash provided by operating activities for the twelve months ended December 31, 2024, was $1,597 million, compared to $1,032 million in 2023[68] - Consolidated cash, cash equivalents, and restricted cash totaled $1.20 billion as of December 31, 2024[18] - Total long-term debt decreased to $21,616 million in 2024 from $22,388 million in 2023[68] - The company reported a total of $20,480 million in debt obligations for 2024, down from $21,006 million in 2023[68] - The company is exploring capital market options to address its debt maturity profile, potentially involving pledging shares in Bausch + Lomb[18] Guidance and Future Outlook - The Company provides full-year 2025 revenue guidance of $9.900 - $10.150 billion, with a revenue growth of 2% - 6% compared to the prior year[20] - Adjusted EBITDA guidance for 2025 is set at $3.525 - $3.675 billion, reflecting a growth of 3% - 7% year-over-year[20] - Adjusted Operating Cash Flow is projected to be between $0.975 - $1.025 billion for 2025[20] Research and Development - CABTREO®, a triple combination product for acne vulgaris, was launched in Canada in October 2024[22] - RED-C, aimed at preventing overt hepatic encephalopathy, is on track for top-line Phase 3 results by early 2026[22] - Amiselimod, a treatment for ulcerative colitis, has met with major regulatory bodies and is awaiting feedback[22] - Thermage® FLX and Clear + Brilliant® Touch are undergoing regulatory approval processes in multiple countries, including Canada and Europe[22] - Research and development expenses for the twelve months ended December 31, 2024, totaled $616 million, slightly up from $604 million in 2023[51] - Research and development expenses for the three months ended December 31, 2024, were $163 million, slightly up from $152 million in 2023, reflecting a growth of 7.2%[54] Non-GAAP Measures - The Company emphasizes the importance of non-GAAP measures for evaluating performance and setting operational goals[29] - Adjusted EBITDA attributable to Bausch Health (non-GAAP) is used to provide a clearer picture of operational performance, excluding nonrecurring items[38] - Adjusted net income (non-GAAP) is utilized for strategic decision-making and evaluating performance trends, highlighting the company's focus on underlying operational results[42] - The company excluded acquisition-related costs and adjustments from its financial results to provide a clearer view of ongoing operations[39] - The Company does not provide reconciliations of projected Adjusted EBITDA to GAAP net income due to forecasting difficulties[20] Cost Management - The company reported a cost of goods sold of $711 million in Q4 2024, compared to $695 million in Q4 2023, indicating a 2.3% increase[51] - Bausch Health's adjusted cost of goods sold for the twelve months ended December 31, 2024, was $2.647 billion, compared to $2.496 billion in 2023, an increase of 6%[54] - Selling, general and administrative expenses for the twelve months ended December 31, 2024, totaled $3.296 billion, compared to $2.917 billion in 2023, marking a 13% increase[54] - The adjusted selling, general and administrative expenses for the three months ended December 31, 2024, were $795 million, up from $740 million in 2023, indicating a rise of 7.4%[54] Tax and Impairments - The company reported a provision for income taxes of $111 million for the three months ended December 31, 2024, compared to $40 million in 2023[62] - The company reported goodwill impairments of $91 million for the three months ended December 31, 2023, which were eliminated in 2024[55] - The company reported a tax effect of non-GAAP adjustments amounting to $(57) million for the twelve months ended December 31, 2024, compared to $25 million in 2023[55]

Analysts on Wall Street project that Bausch Health (BHC) will announce quarterly earnings of $1.12 per share in its forthcoming report, representing a decline of 2.6% year over year. Revenues are projected to reach $2.51 billion, increasing 4.3% from the same quarter last year.Over the last 30 days, there has been an upward revision of 0.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts ...

Core Viewpoint - Bausch Health (BHC) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2024, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Bausch's quarterly earnings is $1.12 per share, reflecting a year-over-year decrease of 2.6%, while revenues are projected to reach $2.51 billion, representing a 4.3% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.75% higher, indicating a collective reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Bausch is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.74%, indicating a bearish outlook from analysts [10][11]. Historical Performance - In the last reported quarter, Bausch exceeded the expected earnings of $1.03 per share by delivering $1.12, achieving a surprise of +8.74%. Over the past four quarters, the company has beaten consensus EPS estimates twice [12][13]. Investment Considerations - Despite the potential for an earnings beat, Bausch does not appear to be a compelling candidate for such an outcome, and investors should consider other factors before making investment decisions [14][16].

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Skincare Devices - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Skincare Devices was valued at USD 14.1 Billion in 2024 and is projected to reach USD 24.5 Billion by 2030, growing at a CAGR of 9.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Report Features: Comprehensive Market D ...

Bausch Health (BHC) closed the last trading session at $7.57, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.50 indicates a 25.5% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $12, with a standard deviation of $2.59. While the lowest estimate indicates a decline of 20.7% from the current price level, the m ...

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX’s pipelin ...

Bausch Health Companies (NYSE: BHC , TSX: BHC:CA ) is one of the undervalued stocks currently, trading only at trailing EV/EBITDA of 8.03x. The expected complete spin-off of its Bausch + Lomb ( BLCO ) will have more benefitHi there! I am an equity research analyst by profession but a trader by heart, with a background in accounting. I try my best to be a responsible investor, guided by my expertise in fundamental and technical analysis. I enjoy surfing and riding the trends about equity, currencies and cryp ...

A month has gone by since the last earnings report for Bausch Health (BHC) . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boo ...

Investors might want to bet on Bausch Health (BHC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Bausch Health (BHC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bausch Health is a member of the Medical sector. This group includes 1024 individual stocks and c ...